How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review

References

• Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191:541–546. doi:10.1001/jama.1965.03080070025007
   PubMed Web of Science ®Google Scholar
• Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555. doi:10.1016/S0140-6736(15)61412-X
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26(49):6266–6273. doi:10.1016/j.vaccine.2008.09.056
   PubMed Web of Science ®Google Scholar
• Edelman R, Deming ME, Toapanta FR, et al. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing. 2020;17:9. doi:10.1186/s12979-020-00179-9
   Web of Science ®Google Scholar
• Wolters B, Junge U, Dziuba S, et al. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21(25–26):3623–3628. doi:10.1016/s0264-410x(03)00399-2
   PubMed Web of Science ®Google Scholar
• United Nations Department of Economic and Social Affairs. World Population Ageing 2019. Available from: https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf. Accessed June 30, 2022.
   Google Scholar
• World Health Organization. Hepatitis B. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed June 30, 2022.
   Google Scholar
• Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–2219. doi:10.1016/j.vaccine.2011.12.116
   PubMed Web of Science ®Google Scholar
• Zuckerman AJ. Chapter 70: hepatitis Viruses. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston: University of Texas Medical Branch at Galveston; 1996.
   Google Scholar
• Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis. 2004;24(Suppl 1):3–10. doi:10.1055/s-2004-828672
   PubMed Web of Science ®Google Scholar
• Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–S101. doi:10.1016/j.jhep.2016.02.021
   PubMed Web of Science ®Google Scholar
• Tan A, Koh S, Bertoletti A. Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med. 2015;5(8):a021428. doi:10.1101/cshperspect.a021428
   PubMed Web of Science ®Google Scholar
• Bengsch B, Chang KM. Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clin Liver Dis. 2016;20(4):629–644. doi:10.1016/j.cld.2016.06.001
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603. doi:10.1093/infdis/151.4.599
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Medley GF, Nokes DJ, et al. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993;253(1337):197–201. doi:10.1098/rspb.1993.0102
   PubMed Web of Science ®Google Scholar
• Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000. doi:10.1093/clinids/20.4.992
   PubMed Web of Science ®Google Scholar
• Hadler SC, Judson FN, O’Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 1991;163(3):454–459. doi:10.1093/infdis/163.3.454
   Web of Science ®Google Scholar
• Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163(5):1138–1140. doi:10.1093/infdis/163.5.1138
   Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55. doi:10.1002/hep.22898
   PubMed Web of Science ®Google Scholar
• Mason WS, Gill US, Litwin S, et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology. 2016;151(5):986–998.e4. doi:10.1053/j.gastro.2016.07.012
   PubMed Web of Science ®Google Scholar
• Carrion AF, Martin P. Viral hepatitis in the elderly. Am J Gastroenterol. 2012;107(5):691–697. doi:10.1038/ajg.2012.7
   Web of Science ®Google Scholar
• Osawa M, Akuta N, Suzuki F, et al. Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus. J Med Virol. 2017;89(12):2144–2148. doi:10.1002/jmv.24890
   PubMed Web of Science ®Google Scholar
• Voulgaris T, Papatheodoridi M, Lampertico P, et al. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int. 2020;40(3):484–495. doi:10.1111/liv.14334
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806. doi:10.1016/j.jhep.2015.11.035
   PubMed Web of Science ®Google Scholar
• Chang Y, Choe WH, Sinn DH, et al. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: a Nationwide, Multicenter, Retrospective Study. J Infect Dis. 2017;216(11):1407–1414. doi:10.1093/infdis/jix506
   Web of Science ®Google Scholar
• Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945–952. doi:10.1136/gutjnl-2017-314904
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475. doi:10.1016/S0140-6736(12)61425-1
   PubMed Web of Science ®Google Scholar
• Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121(20):3631–3638. doi:10.1002/cncr.29537
   Web of Science ®Google Scholar
• Cho H, Ahn H, Lee DH, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. J Viral Hepat. 2018;25(6):707–717. doi:10.1111/jvh.12855
   PubMed Web of Science ®Google Scholar
• Sinn DH, Lee J, Goo J, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology. 2015;62(3):694–701. doi:10.1002/hep.27889
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61(6):1809–1820. doi:10.1002/hep.27723
   PubMed Web of Science ®Google Scholar
• Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57(2):442–450. doi:10.1016/j.jhep.2012.02.033
   PubMed Web of Science ®Google Scholar
• Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol. 2013;19(3):195–209. doi:10.3350/cmh.2013.19.3.195
   Google Scholar
• Su TH, Hu TH, Chen CY, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36(12):1755–1764. doi:10.1111/liv.13253
   PubMed Web of Science ®Google Scholar
• Petersen J, Heyne R, Mauss S, et al. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: a 3-Year Prospective Field Practice Study in Germany. Dig Dis Sci. 2016;61(10):3061–3071. doi:10.1007/s10620-015-3960-x
   PubMed Web of Science ®Google Scholar
• Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–681. doi:10.1016/j.jhep.2017.11.039
   PubMed Web of Science ®Google Scholar
• Lampertico P, Viganò M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013;62(2):290–298. doi:10.1136/gutjnl-2011-301430
   PubMed Web of Science ®Google Scholar
• Chen X, Chen X, Chen W, et al. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol. 2014;86(10):1705–1713. doi:10.1002/jmv.24013
   Web of Science ®Google Scholar
• Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325–1332. doi:10.1136/gutjnl-2013-305517
   PubMed Web of Science ®Google Scholar
• Liu A, Le A, Zhang J, et al. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin Transl Gastroenterol. 2018;9(3):141. doi:10.1038/s41424-018-0007-6
   Web of Science ®Google Scholar
• Nguyen MH, Lim JK, Burak Ozbay A, et al. Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. Hepatology. 2019;69(3):959–973. doi:10.1002/hep.30246
   Web of Science ®Google Scholar
• Wong GLH, Wong VWS, Yuen BWY, et al. An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: a Territory-Wide Study From 2000 to 2017. Hepatology. 2020;71(2):444–455. doi:10.1002/hep.30833
   PubMed Web of Science ®Google Scholar
• Tseng CH, Hsu YC, Ho HJ, et al. Increasing Age and Nonliver Comorbidities in Patients with Chronic Hepatitis B in Taiwan: a Nationwide Population-Based Analysis. Dig Dis. 2021;39(3):266–274. doi:10.1159/000511585
   Web of Science ®Google Scholar
• Fabrizi F, Donato FM, Messa P. Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol. 2017;16(1):21–47. doi:10.5604/16652681.1226813
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin CL, Kao CH. Association Between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis: a Nationwide Population-Based Study. Medicine. 2015;94(50):e2276. doi:10.1097/MD.0000000000002276
   PubMed Web of Science ®Google Scholar
• Lin CW, Huang XL, Liu HL, et al. Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: possible Mechanisms and Clinical Impact. Dig Dis Sci. 2015;60(12):3513–3524. doi:10.1007/s10620-015-3772-z
   PubMed Web of Science ®Google Scholar
• Lampertico P, Chan HLY, Janssen HLA, et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44(1):16–34. doi:10.1111/apt.13659
   PubMed Web of Science ®Google Scholar
• Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and Meta-analysis. Int Immunopharmacol. 2017;42:168–175. doi:10.1016/j.intimp.2016.11.022
   PubMed Web of Science ®Google Scholar
• Law ST, Lee MK, Li KK, et al. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2016;28(2):193–198. doi:10.1097/MEG.0000000000000519
   Web of Science ®Google Scholar
• Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22(3):319–326. doi:10.3350/cmh.2016.0045
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Chan HLY, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956–967. doi:10.1016/j.jhep.2015.01.002
   PubMed Web of Science ®Google Scholar